<DOC>
	<DOCNO>NCT00276614</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study well bortezomib work treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Bortezomib Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine , preliminarily , efficacy bortezomib patient metastatic non-clear cell renal cell carcinoma term objective response rate minimum 2 course treatment . Secondary - Correlate clinical response patient baseline von Hippel-Lindau expression nuclear factor-KB activity . OUTLINE : This open-label study . Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 , 11 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 1 month periodically 2 year . PROJECTED ACCRUAL : A total 27 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically confirm pure nonclear cell renal cell carcinoma ( RCC ) Distant metastatic disease ( Tx , Nx , M1 ) Tumor express wildtype von HippelLindau tumor suppressor gene/protein Measurable disease image scan ( ≥ 1 cm ) Brain metastasis allow provide treated surgery and/or radiation therapy show evidence progression cerebral CT MRI scan 2 month follow surgery and/or radiation therapy . Life expectancy ≥ 3 month Karnofsky performance status ≥ 60 % Negative pregnancy test Fertile patient must use acceptable method contraception No major illness likely limit survival Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1 , 000/mm^3 Hemoglobin ≥ 10 g/dL ( transfusion allow ) Creatinine clearance ≥ 30 mL/min OR creatinine ≤ 2 mg/dL ALT AST ≤ 2.5 time upper limit normal At least 4 week since prior radiotherapy recover More 30 day since prior investigational drug active CNS metastasis pregnant nursing myocardial infarction within past 6 month New York Heart Association class III IV heart failure uncontrolled angina severe uncontrolled ventricular arrhythmia electrocardiographic evidence acute ischemia active conduction system abnormalities Peripheral neuropathy ≤ grade 1 hypersensitivity bortezomib , boron , mannitol history nonRCC malignancy within past 5 year except basal cell carcinoma skin serious medical psychiatric illness would preclude study participation prior cytotoxic chemotherapy cancer concurrent investigational therapy concurrent chemotherapy , immunotherapy , hormonal therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>papillary renal cell carcinoma</keyword>
</DOC>